Inclusion/exclusion criteria

Multiple Sclerosis

ms ribbon

Multiple sclerosis is an inflammatory disease with many different symptoms. Due to this condition myelin sheaths on the axons of the spinal cord and brain develop lesions. Communication between the nerve cells in the spinal cord and the brain is obstructed. MS can progress to varying degrees of physical and cognitive disability.

Stem cell application for MS is available at Angeles hospital in Tijuana. Here is the inclusion and exclusion criteria for MS treatment using stem cells:

Inclusion Criteria

• Males and Females between Age 18 and 80 years.
• Duration of disease: >5 years
• Failure to the currently available -registered- for MS immunomodulatory treatments (ie interferons, Copaxone, immunosuppression): the lack of response to (at least two) of these treatments will be determined/defined by either an increase (deterioration) of at least one degree in the EDSS score during the last year or the appearance of at least two major relapses of MS during the same period of time (under treatment)

Exclusion Criteria

At the time of the screening/enrollment visit #1, patients meeting ANY ONE of the following criteria will be excluded from the study.

• Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
• Inability to undergo fat transfer procedure or have any medical problems that contraindicate the procedure.
• Life expectancy < 6 months due to concomitant illnesses.
• Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
• Active infectious disease and/or known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis. If the panel includes antibodies to the HBV-cAg and HBV-sAg, then an expert will be consulted as to patient eligibility based on the patient’s infectious status
• Any illness which might affect a patient’s survival over the follow-up period
• Any illness which, in the Investigator’s judgement, will interfere with the patient’s ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
• Patients on chronic immunosuppressive transplant therapy
• Patients with severe coagulation disorders
• Systolic blood pressure (supine) ≤90 mmHg;
• Resting heart rate > 100 bpm;
• Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5.
• Active clinical infection being treated by antibiotics within one week of enrollment.
• Cerebrovascular accident within 6 months prior to study entry
• Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
• COPD or severe asthma that would contraindicate surgery
• History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last two years.
• Unwilling and/or not able to give written informed consent.